A joint study by Thermo Fisher Scientific and Tufts Center for the Study of Drug Development revealed that integrating contract development and manufacturing organizations (CDMOs) with contract research organizations (CROs) under a unified platform can shorten oncology drug development timelines by up to 34 months. The Turbo-accelerated process reduces delays between clinical trial phases by eliminating operational 'white space' caused by fragmented decision-making. These findings, presented at BIO International Convention, suggest broader applicability across therapeutic areas and modalities, offering substantial efficiencies in drug development.